Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-on Biologics Showdown In House Set For July 17

This article was originally published in The Pink Sheet Daily

Executive Summary

House tri-committee bill is silent on follow-on biologics, but Rep. Anna Eshoo wants to be heard. Can the germaneness rule save Rep. Waxman from defeat?

You may also be interested in...



And Then There Were 12: Follow-on Biologics Picture Coming Into Focus

It almost seems like the conference committee negotiations for follow-on biologics legislation have begun, but the two actors that the generic industry expects to best represent its issues - Rep. Henry Waxman, D-Calif., and President Obama - are not at the table

And Then There Were 12: Follow-on Biologics Picture Coming Into Focus

It almost seems like the conference committee negotiations for follow-on biologics legislation have begun, but the two actors that the generic industry expects to best represent its issues - Rep. Henry Waxman, D-Calif., and President Obama - are not at the table

Follow-on Biologics: Rep. Eshoo Revising Her Bill To Be Closer To Senate Provision

California Democrat drops data exclusivity to 12 years, plus six months for pediatric studies, and removes requirement for FDA guidance before approval.

Related Content

Topics

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel